Table 2

Magnitude of statistically significant associations found in the unadjusted analysis

OR95% CI
Comparison of baseline, clinical, analytical and radiological characteristics of COVID-19 patients developing acute (myo)pericarditis with respect to COVID-19 patients not developing acute (myopericarditis)
Chest pain13.3467.331 to 24.30
Bilirubin>1 mg/dL4.4552.045 to 9.701
Cardiomegaly in CXR3.2801.710 to 6.270
Pleural effusion in CXR3.1201.250 to 7.770
Age <40 years3.0491.647 to 5.650
Abdominal pain2.9031.234 to 6.826
Leucocyte count >×109 cells/L)2.1871.205 to 3.969
Platelet count >300×109 elements/L)2.1811.149 to 4.138
Pulse oximetry at ED arrival <96%0.5730.329 to 0.996
C-reactive protein >5 mg/dL0.5490.311 to 0.969
Dyslipidaemia0.4790.251 to 0.915
Cough0.4500.263 to 0.770
Fever >38°C0.2940.167 to 0.519
Ground-glass lung opacities in CXR0.2410.131 to 0.442
Dementia0.1540.021 to 1.150
Comparison of baseline, clinical, analytical and radiological characteristics of COVID-19 patients developing acute (myo)pericarditis with respect to non-COVID patients developing acute (myo)pericarditis
Lung interstitial infiltrates in CXR16.337.035 to 37.92
Dysgeusia15.661.603 to 152.9
Ground-glass lung opacities in CXR12.615.125 to 31.04
Anosmia10.280.918 to 115.0
Cough5.4362.973 to 9.937
Lactate dehydrogenase >300 U/L4.4421.928 to 10.24
Abdominal pain3.8441.571 to 9.404
Vomiting3.8441.571 to 9.404
Expectoration3.7921.389 to 10.35
Tachypnoea >20 bpm3.3791.844 to 6.192
Dyspnoea3.0261.770 to 5.174
Length of symptoms >7 days2.8901.565 to 5.348
Lymphocyte count <1 (x109 cells/L)2.8781.603 to 5.165
Aspartate aminotransferase >40 U/L2.5591.242 to 5.274
Fever >38°C2.3161.270 to 4.224
Tachycardia >100 bpm1.8191.017 to 3.254
Age <40 years0.6000.340 to 1.057
Chest pain0.3790.185 to 0.777
Active smoker0.2200.078 to 0.624